Roberta Grande

Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial

Chiara Cremolini, Carlotta Antoniotti, Daniele Rossini et al. · The Lancet Oncology · 2020 · 325 citations · Full text

Medicine, Oncology, Pharmacotherapy +8

Activity and Safety of Cetuximab Plus Modified FOLFOXIRI Followed by Maintenance With Cetuximab or Bevacizumab for <i>RAS</i> and <i>BRAF</i> Wild-type Metastatic Colorectal Cancer

Chiara Cremolini, Carlotta Antoniotti, Sara Lonardi et al. · JAMA Oncology · 2018 · 114 citations · Full text

Medicine, Oncology, Pharmacotherapy +13

Initial Panitumumab Plus Fluorouracil, Leucovorin, and Oxaliplatin or Plus Fluorouracil and Leucovorin in Elderly Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer: The PANDA Trial by the GONO Foundation

Sara Lonardi, Cosimo Rasola, Riccardo Lobefaro et al. · Journal of Clinical Oncology · 2023 · 40 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Palonosetron plus 3-day aprepitant and dexamethasone to prevent nausea and vomiting in patients receiving highly emetogenic chemotherapy

Flavia Longo, Giovanni Mansueto, Vittoria Lapadula et al. · Supportive Care in Cancer · 2010 · 38 citations

Medicine, Pharmacology, Pharmacotherapy +14

Treatment of Metastatic Colorectal Cancer Patients ≥75 Years Old in Clinical Practice: A Multicenter Analysis

Roberta Grande, Clara Natoli, F. Ciancola et al. · PLoS ONE · 2016 · 23 citations · Full text

Medicine, Geriatric Medicine, Oncology +16